DEM Bio is pioneering the next generation of medicines that effectively unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals. Using their proprietary platform, (CHoMP)™, co-culture with human myeloid phagocytes, DEM Bio has discovered and validated new DEM and EM signals that enhance macrophage-mediated elimination of tumor cells. DEM Bio was co-founded by the Longwood Fund and distinguished scientists, Jonathan Weissman, Kipp Weiskopf, and Michael Bassik.